세계의 산전 DNA 시퀀싱 시장 보고서(2025년)
Prenatal DNA Sequencing Global Market Report 2025
상품코드 : 1821697
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

산전 DNA 시퀀싱 시장 규모는 앞으로 수년간 급성장할 것으로 전망됩니다. 2029년에 연평균 성장률(CAGR)은 16.6%를 나타낼 것으로 예측되고 52억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 조기 검진에 대한 소비자 수요, 모체 연령 및 임신 위험 증가, 공공 보건 정책, 규제 지원 및 지침, 데이터 분석 기술 발전 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 연구 개발 노력, 윤리적·규제적 고려사항, 개선된 데이터 해석 공구, 정밀의학 통합, 산전 유전 상담 등이 포함됩니다.

향후 5년간 16.6% 성장이라는 전망치는 이전 예측 대비 0.2% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 독일과 중국에서 개발된 고처리량 시퀀싱 시스템 및 생물정보학 소프트웨어 가격을 상승시켜 미국 내 전장 태아 유전체 시퀀싱 도입을 저해할 수 있으며, 이로 인해 처리 시간 지연과 유전 상담 비용 증가가 발생할 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더 광범위하게 될 것입니다.

예상되는 암 유병률 증가는 산전 DNA 시퀀싱 시장 성장을 촉진할 전망입니다. 통제되지 않은 세포 증식과 확산이 특징인 암은 태아의 염색체 수 이상을 검출하고 태아의 암을 확인하기 위해 산전 DNA 시퀀싱 사용을 촉진합니다. 이 시퀀싱 방법은 개인의 암 발병 가능성에 영향을 미치는 유전적 또는 생식세포 DNA 변화를 밝혀낸다. 예를 들어, 2023년 1월 미국 암 학회(American Cancer Society) 자료에 따르면 암 환자 수가 2021년 189만 8,160명에서 2023년 195만 8,310명으로 증가하여 3.16%의 성장률을 보였습니다. 따라서 암 유병률은 산전 DNA 시퀀싱 시장을 촉진하는 주요 성장 동력으로 작용합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Prenatal DNA sequencing is a method employed to sequence the DNA of an unborn baby, utilizing a blood sample from the mother to unveil the complete genetic code of the fetus. This technique is instrumental in detecting fetal disorders or diseases.

The primary types of prenatal DNA sequencing encompass genetic diseases and nonhereditary diseases. Genetic diseases refer to disorders or diseases caused by mutations in one or more genes. DNA sequencing plays a crucial role in determining whether a gene carries a mutation leading to a specific disorder. Applications of prenatal DNA sequencing include conditions such as hemophilia, Down syndrome, cystic fibrosis, autism, DiGeorge syndrome, AIDS, cancer, and others. Various users, including academic research, clinical research, hospitals and clinics, as well as pharmaceutical and biotechnology companies, employ this technology.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The prenatal DNA sequencing market research report is one of a series of new reports from The Business Research Company that provides prenatal DNA sequencing market statistics, including the prenatal DNA sequencing industry global market size, regional shares, competitors with a prenatal DNA sequencing market share, detailed prenatal DNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal DNA sequencing industry. This prenatal DNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prenatal dna sequencing market size has grown rapidly in recent years. It will grow from $2.5 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to changing patient preferences, medical advancements and research, non-invasive testing adoption, rising maternal age, improved accuracy and reliability.

The prenatal dna sequencing market size is expected to see rapid growth in the next few years. It will grow to $5.23 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to consumer demand for early detection, rising maternal age and pregnancy risks, public health initiatives, regulatory support and guidelines, advancements in data analysis. Major trends in the forecast period include research and development efforts, ethical and regulatory considerations, improved data interpretation tools, precision medicine integration, prenatal genetic counseling.

The forecast of 16.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of whole-genome fetal sequencing by inflating prices of high-throughput sequencing systems and bioinformatics software developed in Germany and China, resulting in slower turnaround times and higher genetic counseling costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in cancer prevalence is set to drive the growth of the prenatal DNA sequencing market. Cancer, characterized by uncontrolled cell growth and spread, prompts the use of prenatal DNA sequencing to detect fetal aneuploidy and identify cancer in the fetus. This sequencing method unveils inherited or germline DNA changes influencing a person's cancer susceptibility. For example, data from the American Cancer Society in January 2023 showed an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth rate of 3.16%. Consequently, the prevalence of cancer acts as a driving force for the prenatal DNA sequencing market.

The increasing birth rate is anticipated to drive the growth of the prenatal DNA sequencing market in the coming years. The birth rate refers to the number of live births per 1,000 individuals in a specific population over a defined period, typically reported annually. Prenatal DNA sequencing is instrumental in detecting genetic abnormalities in unborn fetuses, facilitating informed reproductive choices during childbirth through selective interventions. For example, in January 2023, a report from the Centers for Disease Control and Prevention, a U.S.-based national public health organization, indicated that the United States experienced a 1% rise in registered births, amounting to 3,664,292, compared to the previous year. Consequently, the increasing birth rate is propelling the prenatal DNA sequencing market.

Product innovation is a prominent trend in the prenatal DNA sequencing market, with major companies concentrating on developing innovative solutions to enhance their market standing. Juno Diagnostics, Inc., a U.S.-based health technology company, introduced the noninvasive prenatal screening test 'Hazel' in November 2022. Designed with no risk of miscarriage, the test can be performed as early as 9 weeks into pregnancy using a small blood sample. It screens for common genetic conditions such as Down syndrome, Edwards syndrome, and Patau syndrome.

Major companies in the prenatal DNA sequencing market are pursuing a strategic partnership approach to improve technology integration and broaden their market presence. A strategic partnership generally involves a collaborative relationship among two or more organizations that combine their resources, expertise, and efforts to achieve shared goals or objectives. For example, in December 2023, BillionToOne, a U.S.-based precision diagnostics company, teamed up with a Johnson & Johnson subsidiary, a U.S.-based pharmaceutical firm, for the AZALEA Phase 3 clinical trial of nipocalimab. This trial focuses on pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN). BillionToOne will supply its UNITY Fetal Antigen Non-invasive Prenatal Test (UNITY Fetal Antigen CTA) to screen and determine participant eligibility. HDFN is a rare condition resulting from blood type incompatibility between the pregnant individual and the fetus, which can lead to life-threatening anemia.

In November 2022, Myriad Genetics, Inc., a U.S.-based provider of genetic testing and precision medicine, acquired Gateway Genomics, LLC, a personal genomics and prenatal DNA company. The undisclosed acquisition is expected to enhance Myriad's women's health product portfolio and provide access to personalized genetic tests, strengthening its position in the market.

Major companies operating in the prenatal DNA sequencing market include Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche Ltd, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Myriad Genetics Inc., Invitae Corporation, PerkinElmer Inc., Macrogen Inc., Pacific Biosciences of California Inc., Genewiz LLC, 10x Genomics Inc., Oxford Nanopore Technologies Limited, Thermo Fisher Scientific Inc., Berry Genomics Co. Ltd., Centrillion Technology Holdings Corp., Cynvenio Biosystems Inc., Eurofins LifeCodexx AG, GeneDx Inc., Genoma SA, Helix OpCo LLC, Igenomix S.L., Integrated DNA Technologies Inc.

North America was the largest region in the prenatal DNA sequencing market in 2024. The regions covered in the prenatal dna sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the prenatal dna sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prenatal DNA sequencing market includes revenues earned by entities by provide services such as prenatal next-generation sequencing, whole genome sequencing, DNA extraction, DNA fragmentation, and data collection and sequence analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prenatal DNA Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prenatal dna sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for prenatal dna sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prenatal dna sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Prenatal DNA Sequencing Market Characteristics

3. Prenatal DNA Sequencing Market Trends And Strategies

4. Prenatal DNA Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Prenatal DNA Sequencing Growth Analysis And Strategic Analysis Framework

6. Prenatal DNA Sequencing Market Segmentation

7. Prenatal DNA Sequencing Market Regional And Country Analysis

8. Asia-Pacific Prenatal DNA Sequencing Market

9. China Prenatal DNA Sequencing Market

10. India Prenatal DNA Sequencing Market

11. Japan Prenatal DNA Sequencing Market

12. Australia Prenatal DNA Sequencing Market

13. Indonesia Prenatal DNA Sequencing Market

14. South Korea Prenatal DNA Sequencing Market

15. Western Europe Prenatal DNA Sequencing Market

16. UK Prenatal DNA Sequencing Market

17. Germany Prenatal DNA Sequencing Market

18. France Prenatal DNA Sequencing Market

19. Italy Prenatal DNA Sequencing Market

20. Spain Prenatal DNA Sequencing Market

21. Eastern Europe Prenatal DNA Sequencing Market

22. Russia Prenatal DNA Sequencing Market

23. North America Prenatal DNA Sequencing Market

24. USA Prenatal DNA Sequencing Market

25. Canada Prenatal DNA Sequencing Market

26. South America Prenatal DNA Sequencing Market

27. Brazil Prenatal DNA Sequencing Market

28. Middle East Prenatal DNA Sequencing Market

29. Africa Prenatal DNA Sequencing Market

30. Prenatal DNA Sequencing Market Competitive Landscape And Company Profiles

31. Prenatal DNA Sequencing Market Other Major And Innovative Companies

32. Global Prenatal DNA Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prenatal DNA Sequencing Market

34. Recent Developments In The Prenatal DNA Sequencing Market

35. Prenatal DNA Sequencing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기